nimotuzumab
biocon,daiichi sankyo,oncoscience
['nimotuzumab']
ph 3 trial with nimotuzumab plus gem in 1l for kras wt pdac: os 10.9 vs. 8.5 months hr 0.50 1yos 43.6% vs 26.8% 3yos 13.9% vs 2.7%
interesting data but.. outdated backbone what about those brafmut /kraswt pdac ?
#asco22 
Brazilian Medical Oncologist, Advanced Fellow at GI Medical Oncology Service - MSKCC #gicancers